SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Avis Budget Group, Inc. engages in the provision of vehicle sharing and rental services. It operates through the Americas and International segments. The Americas segment includes vehicle rental and car sharing operations in North America, South America, Central America, and the Caribbean. The International segment is involved in vehicle rental and car sharing operations in Europe, the Middle East, Africa, Asia, and Australasia. The company was founded in 1946 and is headquartered in Parsippany, NJ.

Avis Budget Group Inc

Avis Budget Group (CAR) is seeing extreme volatility as a textbook short squeeze continues, driven by an exceptionally low float with the majority of shares held by a few key institutional investors. The community is intensely focused on the mechanical nature of the rally and the potential for a massive, abrupt retracement, while debating whether the company will issue a share offering to capitalize on the inflated valuation.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is seeing increased investor optimism driven by a positive Medicare Advantage rate announcement and ongoing margin recovery efforts, with the community closely tracking upcoming earnings for further validation of the company's turnaround strategy. Discussions are centered on the potential for institutional accumulation, the impact of AI-driven cost efficiencies, and bullish sentiment surrounding the stock's long-term growth prospects despite lingering regulatory caution.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is seeing a significant surge in momentum driven by aggressive institutional accumulation and anticipation of its upcoming U.S. redomicile, which investors believe will eliminate regulatory and tax-related investment hurdles. The community is actively dismissing a recent short-seller report as a failed attempt to manipulate the stock, focusing instead on the company's critical role in the optical interconnect space and its deep-tech partnerships with major semiconductor players.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending following the unexpected announcement that long-time CEO Tim Cook will step down in 2026 to transition into an Executive Chairman role, with current hardware chief John Ternus tapped as his successor. Investors and community members are actively debating the leadership shift, weighing the implications for Apple's future innovation, AI strategy, and the potential for a new era under an engineering-focused CEO.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as investors react to the company's international expansion efforts in Japan and the Middle East, while speculating on pending FDA decisions and broader potential for its cancer therapy ANKTIVA to reverse T-cell exhaustion. The community remains heavily focused on the high short interest and the potential for a significant price squeeze, viewing the stock as a battleground between long-term retail holders and short sellers.

Applied Digital Corporation

Applied Digital is trending as investors closely monitor an upcoming April 18th lease deadline and potential hyperscaler deal, fueling intense debate over whether news is imminent or if current price action reflects market manipulation. The community remains sharply divided between long-term bullish holders focused on AI infrastructure expansion and day traders attempting to time the stock around high-stakes technical gaps and geopolitical volatility.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor is trending as the community debates its long-term potential in AI power infrastructure versus short-term volatility driven by geopolitical tensions and institutional trading. Traders are actively discussing the stock's consolidation patterns and potential for a breakout, while also analyzing its recent board expansion and the company's strategic positioning within high-efficiency power chip markets.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is currently at the center of significant investor interest due to its dual-focus on lucrative defense-sector contracts and the acquisition of Mynaric, which bolsters its space-based laser communication capabilities. The community is buzzing with anticipation over dual upcoming launches, aggressive revenue growth targets, and the company's evolving role as a vertically integrated prime contractor.

RTX Corp. is an aerospace and defense company, which engages in the provision of aerospace and defense systems and services for commercial, military, and government customers. It operates through the following segments: Collins Aerospace Systems (Collins), Pratt and Whitney, Raytheon Intelligence and Space (RIS), and Raytheon Missiles and Defense (RMD). The Collins segment manufactures and sells aero structures, avionics, interiors, mechanical systems, mission systems, and power controls. The Pratt and Whitney segment includes the design and manufacture of aircraft engines and auxiliary power systems for commercial, military, and business aircraft. The RIS segment is involved in the development of sensors, training, and cyber and software solutions. The RMD segment offers end-to-end solutions to detect, track, and engage threats. The company was founded in 1922 and is headquartered in Arlington, VA.

RTX Corp

Raytheon Technologies Corporation

RTX is gaining momentum as investors focus on its strong order backlog and defense production scale-up, supported by assertive 2026 guidance and consistent contract wins. The community remains broadly bullish, closely tracking how the company's defense-aerospace mix navigates current geopolitical demand and supply chain replenishment cycles.

Strive, Inc. engages in the provision of an asset management Bitcoin treasury. It is focused on maximizing value for shareholders, accumulating bitcoin and outperforming bitcoin over the long run. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani, and Kyle Fairbanks on March 9, 2022 and is headquartered in Dallas, TX.

Strive Inc. - Ordinary Shares - Class A

Strive Inc.

Strive Inc. is currently a focal point for investors tracking Bitcoin proxy plays, with community sentiment driven by bullish expectations of a sustained Bitcoin bull market and the company's recent strategic moves into digital credit. Traders are actively discussing the stock's potential for high volatility and institutional accumulation, frequently debating the impact of management's treasury strategy, past reverse splits, and the potential for a short-term momentum surge.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Dagco added 451,240 shares, making Sellas its second-largest holding at 1.01% of portfolio weight.</li><li>The stake increase comes ahead of AACR presentation of preclinical data on SLS009, Sellas’ CDK9 inhibitor targeting acute myeloid leukemia (AML).</li><li>Investor focus remains centered on the Phase 3 Regal trial of GPS, with 72 of 80 required survival events recorded as of Dec. 26, moving the study closer to topline analysis.</li></ul>Shares of Sellas Life Sciences Group, Inc. (SLS) jumped 5% in premarket trading on Monday after U.S. investment manager Dagco increased its stake by 78% ahead of a major AACR leukemia data catalyst and the closely watched Regal survival trigger.<a href="https://stocktwits.com/symbol/SLS">SLS stock</a> snapped four sessions of gains on Monday to end over 4% lower at $4.99.<h2 class="st-heading-2">Dagco Loads Up Ahead Of SLS009 AACR Data</h2>Data compiled by Quiver Quantitative showed that Dagco added 451,240 shares on Tuesday, bringing its total holdings to 1.03 million shares valued at $4.35 million as of March 31. The position now represents its second biggest holding at 1.01% of Dagco’s disclosed portfolio, placing Sellas among its healthcare bets alongside larger pharma holdings such as Merck, Thermo Fisher Scientific and Johnson &amp; Johnson.The stake increase comes just as Sellas prepares to present new preclinical findings on SLS009, its CDK9 inhibitor for acute myeloid leukemia (AML), during a poster session at AACR in San Diego on Tuesday.According to the company, lab studies showed that SLS009 triggered leukemia-cell death by increasing activity of caspase-3, a protein involved in the body’s natural cell-death process, while lowering survival signals such as MCL-1 and survivin that help cancer cells persist. The drug also showed stronger potency with repeated exposure, with early biological effects appearing within hours and becoming more pronounced over 24 hours.Notably, SLS009 remained active in AML carrying ASXL1 and TP53 mutations, which are genetic subtypes associated with treatment resistance and poorer outcomes.&nbsp;<h2 class="st-heading-2">Regal Survival Countdown In Focus</h2>While the AACR presentation represents a near-term catalyst, investor attention remains firmly centered on the company’s ongoing Phase 3 Regal trial evaluating GPS, an immunotherapy targeting the Wilms Tumor-1 antigen, as a maintenance treatment for AML patients whose disease returned but later entered remission after additional therapy.The event-driven study will begin final analysis once 80 overall-survival events are recorded. Sellas previously said 72 events had been logged as of Dec. 26, bringing the trial closer to the threshold required to initiate topline analysis.CEO Angelos Stergiou previously said that slower accumulation of survival events in oncology trials can sometimes indicate patients are living longer than expected compared with historical assumptions. Once the 80th event occurs, the company plans to proceed with database lock, statistical analysis, trial unblinding and disclosure of topline results.<h2 class="st-heading-2">How Do Retail Traders Feel About SLS?</h2>On Stocktwits, retail sentiment for SLS was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/sls_ss_png_226ba9d4c9.webp" alt="sls ss.png" width="973" height="147"><figcaption>SLS sentiment and message volume as of April 21 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/yG19/message/650823713">noted</a> Diagco’s stake and said, “It's likely clearly see the asymmetric upside with the margin of safety of no REGAL downside.”<stembedurl>https://stocktwits.com/yG19/message/650823713</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/vlucky16/message/650846855">said</a>, “Can't wait to get update on 009, since GPS has been put on hold for an 80th event that might happen from old age.”<stembedurl>https://stocktwits.com/vlucky16/message/650846855</stembedurl>SLS stock has surged over 280% over the past year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-stock-premarket-ross-gerber-brand-backlash-ai-pivot-earnings-check/cZBIOqKRICO">Tesla Stock Rises Premarket: Investor Ross Gerber Says ‘People Just Hate The Brand Now’ As AI Pivot Faces Earnings Reality Check</a>

SLS Stock Jumps Premarket: US Investor Dagco Boosts Stake By 78% Ahead Of Fresh Cancer Drug Data Reveal 

Sellas is now Dagco’s second-largest disclosed holding, putting the small-cap leukemia biotech alongside pharma giants like Merck and Johnson & Johnson.

Equity

AE Wealth Management LLC Sells 63,724 Shares of Thermo Fisher Scientific Inc. $TMO

AE Wealth Management LLC decreased its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 92.4% during the 4th quarter, according to its most recent filing with the SEC. The...

Here's How Much $100 Invested In Thermo Fisher Scientific 20 Years Ago Would Be Worth Today

Unlocking Q1 Potential of Thermo Fisher (TMO): Exploring Wall Street Estimates for Key Metrics

Evaluate the expected performance of Thermo Fisher (TMO) for the quarter ended March 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Zurcher Kantonalbank Zurich Cantonalbank Has $210.67 Million Holdings in Thermo Fisher Scientific Inc. $TMO

Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 54.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3...

Local Pensions Partnership Investment Ltd Cuts Holdings in Thermo Fisher Scientific Inc. $TMO

Local Pensions Partnership Investment Ltd trimmed its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 3.1% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 360,005 shares of the medical research company's stock after sellin...

Oak Harvest Investment Services Decreases Position in Thermo Fisher Scientific Inc. $TMO

Oak Harvest Investment Services decreased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 90.2% in the 4th quarter, according to the company in its most recent...

Thermo Fisher Scientific Inc. $TMO Shares Purchased by Cwm LLC

Cwm LLC lifted its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 60.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 25,627 shares of the medical research company's stock after purchasing an additi...

Ninety One North America Inc. Makes New Investment in Thermo Fisher Scientific Inc. $TMO

Ninety One North America Inc. acquired a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) during the 4th quarter, according to the company in its most recent...

Ninety One UK Ltd Has $517.14 Million Stock Position in Thermo Fisher Scientific Inc. $TMO

Ninety One UK Ltd lifted its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 6.8% in the fourth quarter, according to its most recent disclosure with the SEC. The...

Thermo Fisher Scientific Inc. serves the scientific community through a broad offering of innovative products and services. Thermo Fisher Scientific serves customers working in pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental, industrial, research and development, quality and process control settings. The company’s global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through its brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. The company continuously increases its depth of capabilities across its broad portfolio of innovative products and services and leverages its extensive global channels to address customers’ needs. The company does this through organic investments in research and development, capacity and capabilities and through acquisitions. The company’s goal is to enable its customers to be more productive in an increasingly competitive business environment, enable them to accelerate innovation, solve their challenges and advance their important work. The company’s history roots back to the year 1956 when the business was first established. Thermo Fisher Scientific was formed in 2006 from the merger of Thermo Electron and Fisher Scientific and is headquartered in Waltham, MA.

TMO
Thermo Fisher Scientific Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest TMO News

TMOThermo Fisher Scientific Inc.